
Publisher retracts key study cited by federal judge in FDA abortion pill ruling
By Lauren Taylor (Anchor), Jake Maslo (Video Editor)
Media Landscape
This story is a Media Miss by the right as only 3% of the coverage is from right leaning media. Learn moreBias Summary
- Lorem ipsum dolor sit amet consectetur adipiscing elit turpis habitasse erat taciti, condimentum odio congue phasellus ad vel lacus fames netus mollis.
- Egestas purus ad nunc placerat nisi tristique mattis elementum nam interdum sodales porta, consequat fermentum eleifend molestie dictum turpis vestibulum natoque at iaculis urna.
- Rutrum curabitur vehicula condimentum conubia volutpat sapien orci nulla lacus pharetra placerat, tincidunt mus integer consequat pulvinar vivamus dignissim nunc cubilia risus.
- Dolor amet ac convallis sociosqu dignissim vulputate parturient nunc at fusce himenaeos, maecenas tristique orci aenean pellentesque aliquet sem neque rhoncus venenatis.
- Tempor libero habitasse venenatis justo sollicitudin ullamcorper ante pharetra proin suspendisse, aliquet dolor pellentesque purus felis odio elementum vulputate.
- Netus dui fermentum donec augue interdum est ultricies elementum scelerisque risus sed lacinia molestie porta et, venenatis mattis eleifend vestibulum egestas pulvinar nascetur nulla ullamcorper vulputate odio congue consequat dolor.
- Facilisis integer orci maecenas porttitor erat enim est adipiscing, pulvinar ultrices metus placerat facilisi aliquam litora.
- Quisque est vulputate ac malesuada accumsan hendrerit orci himenaeos ex duis placerat, aliquam phasellus odio potenti iaculis eros sociosqu curae ad.
- Inceptos mauris himenaeos turpis nec lacus placerat molestie dignissim pellentesque neque nascetur at efficitur duis, feugiat ad consectetur morbi sapien sed id tincidunt non lacinia elit venenatis.
Bias Comparison
Bias Distribution
Left
Right
Right
Untracked Bias
Last year, a Texas federal judge’s decision to revoke the Food and Drug Administration’s (FDA) approval of the abortion pill mifepristone ignited a nationwide controversy over abortion rights. The legal skirmish over the pill has escalated further following the retraction of a key scientific paper that played a pivotal role in the case.

Download the SAN app today to stay up-to-date with Unbiased. Straight Facts™.
Point phone camera here
In 2021, Sage Journals published a study suggesting that mifepristone significantly increases the risk of women requiring emergency room care after an abortion. This study was cited by Texas District Judge Matthew Kacsmaryk in his April ruling against the FDA’s approval of the pill. Recently, Sage announced the retraction of this study and two others by lead author James Studnicki, criticizing the research for its lack of scientific rigor and accusing the author of undeclared conflicts of interest.
Sage commissioned two independent experts for a post-publication review of the papers. The experts identified “fundamental problems,” undermining the authors’ conclusions. Studnicki, in a rebuttal shared with Wired, denounced the retractions as “unjustified” and described Sage’s action as a “baseless ideological attack.”
Sage highlighted that Studnicki and his co-authors had declared no conflicts of interest upon submitting their research. However, Studnicki serves as vice president of the Charlotte Lozier Institute, the research arm of Susan B. Anthony Pro-Life America, a prominent anti-abortion organization.
Unbiased news.
Directly to your inbox. Free!
Learn more about our emails. Unsubscribe anytime.
By entering your email, you agree to the Terms & Conditions and acknowledge the Privacy Policy.
Studnicki maintains that his affiliation with anti-abortion groups was “fully known and identified to Sage” at the time of submission.
The future of the Texas ruling now rests with the Supreme Court, following a federal appeals court’s decision that mifepristone should stay accessible to patients while the lawsuit against the FDA proceeds.
The Supreme Court is scheduled to hear arguments on the matter in March, marking the first abortion case since the landmark 2021 Dobbs decision, which overturned Roe v. Wade and ended federal protection for abortion rights.
[LAUREN TAYLOR]
A FEDERAL JUDGE IN TEXAS LAST YEAR REVOKED THE FOOD AND DRUG ADMINISTRATION’S APPROVAL OF THE ABORTION PILL MIFEPRISTONE — TOUCHING OFF A FIRESTORM OF DEBATE OVER ABORTION RIGHTS.
NOW, A PUBLISHED SCIENTIFIC PAPER AT THE CENTER OF THE ABORTION PILL LEGAL BATTLE HAS BEEN RETRACTED.
IN 20-21, SAGE JOURNALS PUBLISHED A STUDY PURPORTING TO SHOW MIFEPRISTONE SIGNIFICANTLY INCREASES WOMEN’S RISK OF EMERGENCY ROOM VISITS FOLLOWING AN ABORTION.
TEXAS DISTRICT JUDGE MATTHEW KACSMARYK CITED THE STUDY IN HIS APRIL RULING AGAINST THE F-D-A’S APPROVAL OF THE PILL.
THIS WEEK, SAGE ANNOUNCED IT WAS RETRACTING THE STUDY — AND TWO OTHERS — BY LEAD AUTHOR JAMES STUDNICKI. THE PUBLISHER CLAIMING THE STUDIES SHOWED A “LACK OF SCIENTIFIC RIGOR” AND ACCUSING THE AUTHOR OF UNDECLARED CONFLICTS OF INTEREST.
ACCORDING TO SAGE, TWO INDEPENDENT EXPERTS CONDUCTED A POST-PUBLICATION REVIEW OF THE THREE PAPERS AND FOUND WHAT THEY CALLED “FUNDAMENTAL PROBLEMS” THAT INVALIDATED THE AUTHORS’ CONCLUSIONS.
IN A DETAILED REBUTTAL TO SAGE PUBLISHING SHARED WITH “WIRED,” STUDNICKI CALLED THE RETRACTIONS “UNJUSTIFIED.” HE LATER CHARACTERIZED SAGE’S MOVE AS A “BASELESS IDEOLOGICAL ATTACK.”
WHEN IT COMES TO THE ALLEGATIONS OF CONFLICT OF INTEREST, SAGE SAID STUDNICKI AND THE OTHER AUTHORS DECLARED THEY HAD NOT CONFLIGHTS WHEN THEY SUBMITTED THE STUDY.
STUDNICKI IS VICE PRESIDENT OF THE CHARLOTTE LOZIER INSTITUTE, THE RESEARCH ARM OF SUSAN B. ANTHONY PRO-LIFE AMERICA, A LEADING ANTI-ABORTION GROUP.
ACCORDING TO STUDNICKI, HIS AND HIS FELLOW AUTHORS’ CONNECTION TO ANTI-ABORTION GROUPS WAS “FULLY KNOWN AND IDENTIFIED TO SAGE” WHEN THE PAPERS WERE SUBMITTED.
THE TEXAS RULING IS NOW IN THE HANDS OF THE SUPREME COURT AFTER A FEDERAL APPEALS COURT RULED MIFEPRISTONE SHOULD REMAIN AVAILABLE TO PATIENTS WHILE THE LAWSUIT AGAINST THE F-D-A CONTINUES IN THE COURTS.
JUSTICES ON THE HIGH COURT ARE SET TO HEAR ARGUMENTS OVER THE ISSUE NEXT MONTH. IT WILL BE THE FIRST ABORTION CASE THE COURT HAS RULED ON SINCE THE 20-21 DOBBS DECISION WHICH OVERTURNED ROE V WADE — EFFECTIVELY REMOVING FEDERAL PROTECTION FOR ABORTION RIGHTS.
Media Landscape
This story is a Media Miss by the right as only 3% of the coverage is from right leaning media. Learn moreBias Summary
- Euismod tristique class auctor integer adipiscing egestas diam praesent odio metus varius, id mollis litora dictum venenatis vel potenti nostra sapien ornare.
- Feugiat nunc venenatis dolor convallis leo dapibus eget habitant elit montes pellentesque vitae, fermentum mus semper rhoncus nam praesent nisi a habitasse turpis rutrum.
- Pretium ante aliquam id fringilla fusce cras enim lacus potenti viverra convallis, finibus congue malesuada fermentum dui elementum ridiculus dolor molestie efficitur.
- Class integer aliquet urna sollicitudin ridiculus mauris posuere dolor habitasse iaculis curae, parturient dapibus enim consectetur nascetur libero amet duis faucibus at.
- Porttitor vehicula odio at facilisi donec ultricies nec viverra interdum suspendisse, libero class nascetur nunc phasellus mollis habitant mauris.
- Sapien platea mus pulvinar eu montes luctus tortor habitant sem efficitur ullamcorper maximus rhoncus vitae hac, at eget semper nisi feugiat dui lacinia lacus ultricies mauris mollis litora fermentum class.
- Morbi malesuada enim parturient placerat metus maecenas luctus egestas, dui nulla risus convallis laoreet quisque taciti.
- Facilisis luctus mauris aliquet mattis blandit ligula enim curae ipsum quis convallis, quisque dictum mollis vestibulum turpis pharetra sollicitudin ex venenatis.
- Volutpat tincidunt curae praesent tellus potenti convallis rhoncus ridiculus nascetur duis lacinia habitasse cubilia quis, hendrerit venenatis adipiscing condimentum cras ullamcorper lectus finibus justo maximus diam at.
Bias Comparison
Bias Distribution
Left
Right
Right
Untracked Bias
Straight to your inbox.
By entering your email, you agree to the Terms & Conditions and acknowledge the Privacy Policy.